# ZEISS announces availability of CT LUCIA 621P in Japan, expanding its broad ZEISS Cataract Workflow

- Link: https://www.thailand-business-news.com/pr-news/zeiss-announces-availability-of-ct-lucia-621p-in-japan-expanding-its-broad-zeiss-cataract-workflow
- Published: 2026-10-22T20:00:00+07:00
- Author: PR Newswire

|   |

The ZEISS CT LUCIA 621P monofocal intraocular lens (IOL) is added to the ZEISS Cataract
Workflow in the Japanese market, supporting good visual outcomes for patients.

JENA, Germany and TOKYO, Oct. 22, 2026 /PRNewswire/ — ZEISS Medical Technology announced
today the commercial availability of the CT LUCIA^(®) 621P monofocal IOL from ZEISS
in Japan, expanding the ZEISS Cataract Workflow in the Japanese market to support
good visual outcomes. The ZEISS CT LUCIA 621P will be showcased at the 80th Annual
Congress of Japan Clinical Ophthalmology (JCO) in Kyoto, Japan, from Oct. 29 – Nov.
1, 2026.

 [⌊ZEISS CT LUCIA 621P monofocal IOL⌉](https://mmx.prnasia.com/media/MS2018726/CT-LUCIA-621P-frontal-Image.jpg?id=OA3034248&p=medium600)

ZEISS CT LUCIA 621P monofocal IOL

"The introduction in Japan of the CT LUCIA^(®) IOL from ZEISS marks an important
step in our ambition to help shape the future of ophthalmology in this important
market," says Andreas Völker, Head of the Ophthalmology Strategic Business Unit,
ZEISS Medical Technology. "By bringing meaningful innovation to ophthalmologists
in Japan, we aim to empower them with more choices to advance patient care and deliver
better outcomes for the people in their care. As we continue to grow our global 
footprint, we are putting ophthalmologists and their patients at the center of everything
we do."

"This news represents an important expansion of our ZEISS Cataract Workflow for 
ophthalmic surgeons and their patients throughout Japan," says Vincent Mathieu, 
CEO, ZEISS Group Japan. "We have listened closely to the needs of ophthalmic professionals
and are excited to further expand our portfolio with the ZEISS CT LUCIA 621P."

The ZEISS CT LUCIA 621P monofocal IOL uses a proprietary ZEISS Optic (ZO) Asphericity
Concept to account for the natural misalignment between the cornea center and the
optical axis of the eye, supporting consistent visual outcomes^(1) across a wide
range of patient profiles. The monofocal IOL features a reinforced optic-haptic 
junction, coupled with step-vaulted C-loop haptics, designed to enable easy centering
while maximizing direct capsular contact, thus helping to optimize stability and
support a consistent position in the bag^(2).

For more information about the ZEISS CT LUCIA 621P IOL and its commercial availability
in the Japanese market, speak to your account representative or visit [here](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4804220-1&h=1943356032&u=https%3A%2F%2Fwww.zeiss.co.jp%2Fmeditec%2Fc%2Fct-lucia-621p-c-00016561.html&a=here).

_^(1)__The data is taken from a simulation. The transferability of the results of
such a simulation to patients with an actual implanted intraocular lens has not 
yet been scientifically proven. Whether the simulated impressions correspond to 
the actual visual impressions must be clarified in future invasive studies. [en-
OUS\_32\_025\_0057VI]^(2)Based on cohort data collected from Dr Cuttitta (University
of Palermo, Italy) after implantation of CT LUCIA 621P IOLs in sixty eyes. Internal
report on CT LUCIA 621P data collection (Dr Cuttitta) – Version 1.1 dated 19.11.2019[
en-OUS\_32\_025\_0057VI]

**Contact for investorsSebastian Frericks
Director Investor RelationsCarl Zeiss 
Meditec AGPhone: +49 3641 220 116Mail: [investors.med@zeiss.com](https://www.thailand-business-news.com/pr-news/investors.med@zeiss.com)

**Contact for the pressFrank Smith
Head of Global Communications Ophthalmology, 
Carl Zeiss Meditec Inc.Phone: +49 3641 220 331Mail: [press.med@zeiss.com](https://www.thailand-business-news.com/pr-news/press.med@zeiss.com)

[www.zeiss.com/newsroom](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4804220-1&h=2379765312&u=http%3A%2F%2Fwww.zeiss.com%2Fnewsroom&a=www.zeiss.com%2Fnewsroom)

**Brief Profile**

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX
of the German stock exchange, is one of the world’s leading medical technology companies.
The Company supplies innovative technologies and application-oriented solutions 
designed to help doctors improve the quality of life of their patients. The Company
offers complete solutions, including implants and consumables, to diagnose and treat
eye diseases. The Company creates innovative visualization solutions in the field
of microsurgery. With 5,730 employees worldwide, the Group generated revenue of 
€2,066.1m in fiscal year 2023/24 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in 
Germany and abroad; more than 50 percent of its employees are based in the USA, 
Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore,
India and the Carl Zeiss Innovations Center for Research and Development in Shanghai,
China, strengthen the Company’s presence in these rapidly developing economies. 
Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59
percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical
and optoelectronic industries.

For further information visit: [www.zeiss.com/med](https://edge.prnewswire.com/c/link/?t=0&l=en&o=4804220-1&h=4216034443&u=http%3A%2F%2Fwww.zeiss.com%2Fmed&a=www.zeiss.com%2Fmed)

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [ZEISS announces availability of CT LUCIA 621P in Japan, expanding its broad ZEISS Cataract Workflow ](http://www.prnasia.com/story/archive/5078779_AE78779_0?rand=184833)